Healthcare / Biotech
IQVIA
30-Second Executive Brief
Executive Assessment
IQVIA functions as an established institution within Healthcare / Biotech, backed by 47% sourcing coverage, with accelerating strategic relevance.
- Maintains 3 mapped relationships across the graph
- 47% sourcing coverage across sourced relationships
- Tracked as established institution within the Healthcare / Biotech category
Executive Snapshot
- Strategic Role
- Established Institution
- Sourcing Coverage
- 47%
- Ecosystem Influence
- High
- Strategic Momentum
- Accelerating
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 3
- Technology Domains
- 2
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
Clinical research organization and healthcare data analytics company. IQVIA reported Q2 2026 revenue of $4.37 billion, up 8.7% year-over-year, with adjusted diluted EPS of $3.15 beating estimates, R&D Solutions net new bookings up 19% to $3.15 billion, and raised full-year 2026 guidance to $17.15-17.35 billion in revenue and $12.80-13.00 in adjusted EPS.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
1 source
- Investing.com — IQVIA tops Q2 2026 estimates and raises outlooknews
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Sep 7, 2026
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding IQVIA — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
IQVIA's Timeline
A sourced, dated history of IQVIA's key moments — founding to present.
Jul 2026 · Reports Q2 2026 revenue growth, raises guidance
IQVIA reported second-quarter 2026 revenue of $4.37 billion, up 8.7% year-over-year, with adjusted diluted EPS of $3.15 beating estimates and R&D Solutions net new bookings up 19% to $3.15 billion, raising full-year 2026 guidance.